Sorry, Shkreli: Supreme Court rebuffs ex-pharma CEO's final appeal

shkreli
The U.S. Supreme Court refused to hear former Retrophin CEO Martin Shkreli's appeal to overrun his 2017 fraud conviction. (Getty)

Martin Shkreli, the disgraced former CEO of Retrophin currently serving a seven-year sentence for securities fraud and conspiracy, was hoping for a SCOTUS Hail Mary after multiple appeals fell flat. Turns out the court wasn't interested in hearing Shkreli's pleas at all. 

The U.S. Supreme Court on Monday denied hearing Shkreli's appeal to overturn his 2017 fraud conviction after his disastrous run as head of biotech Retrophin. Shkreli was also forced to forfeit $7.36 million in his conviction.

With that final rebuff, Shkreli will likely see the inside of a jail cell for the next five years––a sentence that could grow longer after he was accused of running his business from behind bars. 

RELATED: Shkreli's jail-cell business dealings draw scrutiny from the feds: WSJ

Suggested Articles

Dogged by opioid liabilities, Mallinckrodt is reportedly looking to restructure its U.S. generics unit to cover its debts and possible settlements.

Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk.

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.